A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment following disease progression during anthracycline-based neoadjuvant chemotherapy.

•There is no standard therapy for locally advanced TNBC showing disease progression during NAC.•We presented a case of locally advanced TNBC showing pCR to weekly paclitaxel with bevacizumab treatment showing PD during standard NAC.•This report suggests the potential of bevacizumab in response-guided sequential therapy and this finding should be confirmed in clinical trial.